Mechanisms and Cross-Organ Physiology of GLP-1, GIP, Glucagon and Amylin in Health, Obesity and Type 2 Diabetes

Peptide agonists of the incretin and amylin systems have become powerful tools for interrogating whole-body metabolic regulation. Beyond glucose and body weight, they act across neural, pancreatic, hepatic, adipose, muscular, and gastrointestinal physiology.This Research Topic asks: How do incretin and amylin therapies change whole-body physiology, and why do their effects differ between tissues and people?We particularly welcome mechanistic experimental, translational, and integrative physiology studies that explain how peptide agonists act across organs, rather than studies limited to clinical efficacy or body-weight outcomes. Studies examining mechanisms of variable response, treatment tolerance, as well as studies comparing single, dual, and triple agonists, or are especially welcome.Contributions may address one or more of the following five interconnected themes:1. Brain-to-metabolism signallingNeural circuits, appetite, autonomic control, nausea, reward, and energy expenditure under GLP-1, GIP, glucagon, or amylin signalling.2. Islet adaptation and glucagon biologyBeta-cell function, insulin secretion, alpha-cell regulation, islet stress, and responses to single, dual, or triple agonists.3. Peripheral tissue mechanismsSubstrate partitioning, thermogenesis, and systemic insulin sensitivity.4. Gut and gut-brain physiologyGastric emptying, nutrient sensing, vagal signalling, gut peptides, and treatment tolerance.5. Why responses varyMechanisms underlying weight-loss response, non-response, durability, adverse effects, sex differences, obesity, and type 2 diabetes. Topic editors: Mantas Malinauskas, Almantas Maleckas Source: https://www.frontiersin.org/research-topics/83877/mechanisms-and-cross-organ-physiology-of-glp-1-gip-glucagon-and-amylin-in-health-obesity-and-type-2-diabetes